Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
For instance, a number of ongoing or completed trials are evaluating inhibitors of the PI3K-AKT-mTOR cascade, such as gedatolisib (NCT03065062) in advanced solid tumors, capivasertib (NCT04305496) in hormone receptor-positive breast cancer, and alpelisib (NCT02437318), which has shown efficacy in advanced breast cancer and is already approved for PIK3CA-mutated cases
GHK-Cu Antioxidative Potential Data suggests GHK-Cu may interact with reactive oxygen and nitrogen species, potentially moderating oxidative stress in experimental setups
10.1164/rccm.201003-0442OC
2016 Jan;54(5):73953
US$ 20.45
US$ 23.87
US$ 21.89
US$ 26.67
US$ 23.79
US$ 26.45
US$ 24.22
US$ 26.33
US$ 28.53
